HLB

028300KOSDAQ의료용품 및 기타 의약 관련제품 제조업

47.1 / 100

Reference Date: 2026-07-24

Financial Score12.5 / 40

News Sentiment17.6 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 40.4% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

HLB operates in four key sectors: healthcare, biotechnology, shipbuilding, and media commerce. The company produces and sells a range of products, including in-vitro diagnostic medical devices, oncology drugs like Rivoceranib and RLY-4008, specialty ships, and beauty devices. In the biotechnology sector, the company focuses on innovative drug development, while the shipbuilding division designs and manufactures specialty vessels and safety equipment.

Number of Employees

151people

Average Salary

60.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.184.0Point

PBR

8.08Industry Average 1.090.0Point

7.4x industry avg (risky)

ROE

-41.07Industry Average -4.893.5Point

8.4x industry avg (excellent)

Debt Ratio

17.82Industry Average 6.860.0Point

2.6x industry avg (risky)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲41.2% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -30.1% (declining, 3yr)

Detailed News Sentiment

43 totalPositive 14Neutral 3Negative 26Average Sentiment Score 70.5

Negative
“결국 망했습니다” “제발 살려달라” -90% 충격적 수익률…‘국민.....
코오롱티슈진의 TG-C 임상 실패로 인해 개미 투자자들의 절망적인 반응과 함께 주가가 급격히 하락했다.
Negative
개미는 오늘도 "팔자" 1조 순매도…코스피 6900선 하회[장중시황]
개인 투자자들의 대규모 매도로 인해 HLB 주가가 하락 압력을 받고 있다.
Positive
HLB 진양곤, 계열사 주식 매입…주가 하락 속 '책임경영' 강화
HLB 진양곤 의장의 계열사 주식 매입은 책임경영 강화 신호로 해석되어 주가 하락에도 불구하고 긍정적 영향을 미침.

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 30,000Won52-week high 68,20052-week low 25,650

1-month return0.0Point

1m -40.36% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-16
Neutral전환가액의조정2026-07-16
Neutral전환가액의조정2026-07-15
Neutral기타경영사항(자율공시) (HLB 간암 1차 치료제(리보세라닙,캄렐리주맙 병용요법)FDA로부터 보완요구서한(CRL,Complete Response Letter)수령)2026-07-10
Neutral기업설명회(IR)개최2026-07-08